ASH 2021 | Update on TRANSFORM: liso-cel vs SOC in R/R LBCL

Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, outlines the findings of the prespecified interim analysis of TRANSFORM, a Phase III trial comparing the efficacy and safety of lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy versus standard of care (SOC) treatment with salvage chemotherapy followed by autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) (NCT03575351). Dr Kamdar explains that the study met its primary endpoint of event-free survival (EFS), with a median EFS of 10.1 months in the liso-cel arm vs 2.3 months in the SOC arm. In addition, patients treated with liso-cel experienced statistically significant improvements in complete response (CR) rate and progression-free survival (PFS), with a trend in overall survival (OS) favouring liso-cel. The safety profile of liso-cel was manageable, with no grade 4 or 5 cytokine release syndrome (CRS) or neurological adverse events. This data suggests liso-cel as a potential new SOC for patients with R/R LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.